Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Intratumoral Administration of Hu14.18-IL2, With Local Radiation, Nivolumab and Ipilimumab in Subjects With Advanced Melanoma

NCT03958383 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT03958383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03958383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Intratumoral Administration of Hu14.18-IL2, With Local Radiation, Nivolumab and Ipilimumab in Subjects With Advanced Melanoma
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 1/2
Overall status
Terminated
Start date
January 30, 2020
Completion date
December 9, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma